Sun Pharmaceutical Industries registered a net profit of Rs 394 crore for the quarter ended March 31, marginally lower than the Rs 394.9 crore in the corresponding period the previous year. Sales declined 2.2 per cent to Rs 1,109 crore, as against Rs 1,134 crore a year ago.
The drop in revenues was triggered by the decline in sales in its US subsidiary Caraco, stated Sun Pharma.
For the full year, the consolidated net profit declined 25.67 per cent to Rs 1,351.08 crore (from Rs 1,817.73 crore in 2008-09). Net sales decreased 3.9 per cent to Rs 4,102.77 crore from Rs 4,272.30 crore on a year-on-year basis.
Sun recommended a dividend of Rs 13.75 for each equity share of Rs 5 for the year ended March 31. It also issued a growth guidance of 18-20 per cent for 2010-11. The company would file 30 new products for the US market and spend Rs 200 crore for capacity expansion programmes during the year.
